BioStem Q3 revenue falls 43%, net income sinks

BioStem Technologies

13/11/2025 21:18

Overview

BioStem Q3 2025 revenue fell 43% yr/yr

Net income for Q3 2025 was $0.8 mln compared to $6.8 mln a year earlier

Company's gross profit margin improved to 88.5% from 77% in Q3 2024

Outlook

BioStem expects top-line readout for BioREtain venous leg ulcer trial in Q1 2026

Company plans to launch American Amnion product in Q4 for VA partnership

BioStem cites reimbursement uncertainty and competition as challenges for wound care

Result Drivers

PRODUCT VOLUME GROWTH - Achieved 40% growth in product volume quarter-over-quarter

GROSS PROFIT MARGIN - Improved gross profit margin due to product mix shift towards products without licensing fees

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$10.50 mln
$51.30 mln (1 Analyst)
Q3 EPS
$0.03
Q3 Net Income
Miss
$800,000
$4.63 mln (1 Analyst)

Analyst Coverage

Wall Street's median 12-month price target for Biostem Technologies Inc is $25.50, about 81.8% above its November 12 closing price of $4.65

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release: ID:nGNX4VsBgJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)